The RheoSwitch|[reg]| Therapeutic System (RTS) is used to regulate both the timing and level of gene expression in response to a systemically delivered small molecule ligand, Activator Drug. This inducible gene regulation system may have utility in human gene therapies that require a specifically regulated level of gene expression, where it is desirable to terminate the therapy when it is no longer needed, or where continuation of the therapy would be unsafe. The version of RTS used in these studies was comprised of an ecdysone receptor (EcR) fused to a GAL4 DNA binding domain, a chimeric retinoid X receptor fused to a VP16 activation domain (pVP16-Hs- LmRXR) , a human secreted alkaline phosphatase (hSEAP) reporter gene placed under the control of a 6xGAL4 response element, and a transthyretin minimal promoter (p6xGAL4-TTR-SEAP). The RTS was electroporated into the quadriceps of C57BL/6 mice and Activator Drug was administered by either intraperitoneal (IP) injection, intramuscular (IM) injection, subcutaneous injection, oral gavage, or administration in the rodent chow. Although ligand-dependent gene expression was observed by all five routes of administration, Activator Drug mixed in chow was easiest to administer, could be administered continuously and may mimic administration by capsule. As an example, six groups of mice (n = four/group) were administered various concentrations of Activator Drug in rodent chow 38 days after RTS electroporation. Activator Drug was given at a rate of 300, 150, 100, 50, 25, or 12.5 mg/kg chow for 21 days, corresponding to approximate total daily Activator Drug doses of 45, 23, 15, 8, 4 and 2 mg/kg/day, respectively. In this study, both the rate of ligand-mediated induction and the magnitude of ligand-mediated hSEAP expression were dependent on the concentration of ligand in the chow. Human SEAP reached a ligand- dose dependent plateau in mice receiving 100, 150, or 300 mg/kg chow two weeks after initiation of ligand administration. The threshold for induction was observed with 50 mg Activator Drug/kg chow, which showed a small induction of hSEAP that was slightly above background. In another long-term expression study, four groups of severe combined immunodeficient (SCID) mice (n = four/group) were administered Activator Drug in chow or by single IP injection at various times after electroporation. Activator Drug administration was started at 3, 32, or 76 days after RTS electroporation. In mice receiving Activator Drug by IP injection, gene expression could be cycled on and off by repeated IP administration. Likewise, gene expression could be similarly cycled when mice were put on and taken off chow containing Activator Drug. Gene expression remained |[ldquo]|on|[rdquo]| when mice were chronically maintained on chow containing Activator Drug. These studies establish that ligand-dependent induction of transgene expression can be obtained by various routes of ligand administration, and that gene expression can be sustained for long periods of time by chronic administration of ligand in chow. Further, the results demonstrate that transgene expression under control of RTS can be cycled on and off by repeat exposure to Activator Drug.
Read full abstract